Publication details
Macugen v léčbě vlhké formy věkem podmíněné makulární degenerace
| Title in English | Macugen in treatment of wet form of age related macular degeneration |
|---|---|
| Authors | |
| Year of publication | 2008 |
| Type | Peer-reviewed scientific article |
| Magazine / Source | Oftalmochirurgie |
| MU Faculty or unit | |
| Citation | |
| Field | ORL, ophthalmology, stomatology |
| Keywords | age related macular degeneration; choroidal neovascular membrane; vascular endothelial growth factor; pegaptanib |
| Description | Discovery of endothelial growth factor antagonists radical affected therapy of the wet form of age related macular degeneration. The first approved antagonist is pegaptanib (Macugen) that selectively blocked VEGF-165 isoform. This isoform is responsible for initialising of pathological neovascularization. |